Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
User Fees FDA Regulation

PDUFA VII Talks To Begin With COVID-19, Other Familiar Issues To Consider

  • Analysis

Executive Summary

US FDA staffing problems and patient engagement enhancements will be listed as priorities during reauthorization kick-off meeting.

You may also be interested in...



Pandemic Taking Its Toll On The US FDA’s Non-Pandemic Work, Alkermes CEO Says

Last year was not the greatest performance by the agency outside of COVID-19, Richard Pops tells BIO conference.

US FDA Drug Review Goals Should Be Faster In PDUFA VII, Industry Negotiators Propose

Sponsor representatives also want postmarketing discussions moved to earlier in the assessment cycle.

A More Perfect Meeting: Industry Seeks Additional PDUFA VII Metrics To Improve Communications

Will the US FDA agree to more structured communications amid its struggles with the existing meeting workload?

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
User Fees FDA Regulation
UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By